Diligence memo · auto-generated · as of July 2, 2026

BioPharma Manufacturing Solutions Inc.

BioPharma Manufacturing Solutions Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

BioPharma Manufacturing Solutions Inc. operates in Pharmaceuticals, based in SEAL BEACH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

BioPharma Manufacturing Solutions Inc. has raised $797K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $401K on 2011-09-01.

Most recent recorded round closed around 2011-09-01.

Valuation (modeled)modeled

Provath models BioPharma Manufacturing Solutions Inc. at approximately $19M (range $224K–$215M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Pharmaceuticals companies in 2010–2012 (71 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 14.8 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 17% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: Dermal Life, LLC, Armgo Pharma Inc, Third Day Healing Holdings LLC, Dermamedics Llc, China Yongxin Pharmaceuticals Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.